By staff writers

December 18, 2014 -- Radiation oncology firm Elekta has received clearance for its Flexitron brachytherapy platform from the China Food and Drug Administration (CFDA).

China has a high prevalence of gynecologic cancers, as well as lung, breast, colorectal, and esophageal cancers, Elekta said. There are approximately 130,000 new cervical cancer patients each year in China, and approximately 40,000 Chinese patients are treated with brachytherapy annually, according to the firm.

Copyright © 2014

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking